Can Metformin Make You Live Longer? The Truth Explained

Updated with Spanish and Mandarin audio on November 23, 2025.

🎧 ▶️ Press play below to listen in English.

🇪🇸 Español (Latinoamérica)

La relación entre metformina y la longevidad ha despertado gran interés, y este artículo explica lo que realmente sabemos sobre “metformina longevidad” y si puede ayudarte a vivir más.

Presiona el botón de reproducir para escuchar.

🇨🇳 中文（简体）

关于“二甲双胍 延长寿命”的讨论越来越多，这篇文章将带你了解科学证据，看看这种药物是否真的能帮助你活得更久。

请按下方的播放按钮收听。

What the Science Actually Says

For years, headlines have called metformin the “miracle anti-aging pill.” It’s the most prescribed diabetes drug in the world, cheap, safe, and even rumored to help you live longer. But is that really true?

The short answer: No randomized human trial has proven that metformin extends lifespan. Several newer studies—especially those with better methods—suggest the early “longevity” signals were likely biased or over-interpreted.

Let’s unpack what the evidence really shows.

1. The Best Randomized Evidence: 21 Years of DPP and DPPOS

The Diabetes Prevention Program (DPP) began in the 1990s. It followed over 3,200 adults with prediabetes, randomly assigned to:

• Lifestyle change (diet + exercise)
• Metformin 850 mg twice daily
• Placebo

After 2.8 years, metformin reduced the risk of developing diabetes by 31%, and lifestyle change by 58%. Great result—so far.

But the follow-up study, DPP Outcomes Study (DPPOS), tracked participants for over 21 years. The big question: did metformin help them live longer or avoid heart attacks, strokes, or death?

The answer: no.

“Metformin and lifestyle intervention did not significantly reduce major cardiovascular events or all-cause mortality compared with placebo.”
— Diabetes Care, 2022 【https://pubmed.ncbi.nlm.nih.gov/35603600/ (Knowler et al., 2022)】

So even though metformin delayed diabetes, it did not reduce deaths or heart disease in the long run.

---

2. Why Early “Metformin = Longevity” Studies Were Misleading

In 2014, a widely shared BMJ study claimed that people with diabetes taking metformin lived longer than healthy non-diabetics. That created a media storm.

But the study wasn’t randomized—it was observational, which means doctors chose who got metformin. Later analyses showed that the survival advantage came from “immortal time bias.”

What’s that?

It’s when the study design accidentally gives one group a “free period” where they can’t die before being counted. To get metformin, you must survive long enough after diagnosis to start it—so the metformin group automatically looks healthier.

When researchers later corrected for this bias, the supposed longevity benefit disappeared.

“When immortal time bias was removed, metformin’s survival advantage was no longer significant.”
— Pharmacol Research, 2021 【https://pubmed.ncbi.nlm.nih.gov/33453371/ (Wang et al. 2021)**】

This bias problem has appeared in many metformin-and-cancer studies too. Once corrected, the apparent lower cancer mortality often vanished (Zhang et al., Cancer Med, 2019).

---

3. Observational Studies vs. Randomized Trials

Evidence Type	What It Shows	Problem
Randomized Trials (RCTs)	Metformin delays diabetes but doesn’t reduce mortality (DPP/DPPOS).	Gold standard; no survival benefit found.
Observational Studies	Often report longer survival in metformin users.	Affected by immortal time bias, healthier-user bias, and unmeasured confounders.
Mendelian Randomization / Genetic Proxies	Some weak signals for beneficial metabolic pathways.	Suggestive, not proof of life extension.
Target Trial Emulations	Better designed observational studies; one 2025 trial showed modest benefit in older women.	No placebo control; residual bias remains.

---

4. Newer Studies Bring More Realism

A 2025 target-trial emulation at UC San Diego studied older women with diabetes. Those who took metformin were 30% more likely to reach age 90 compared with those on sulfonylureas (drugs like glipizide).

But the authors cautioned: there was no placebo comparison, and the results could still be influenced by healthier-user bias (University of California San Diego News Center, 2025).

Meanwhile, a 2023 Welsh cohort with 20-year follow-up found that diabetics on metformin had shorter life expectancy than matched non-diabetics—metformin only looked better when compared with other diabetes drugs (Stevenson-Hoare et al., BMC Public Health, 2023).

• Prescriptions that Promote and Pharmaceuticals that Prevent Ischemic Preconditioning
• Intermittent Fasting vs. Sulfonylureas: Heart Attack Outcomes
• Intermittent Fasting vs Diabetes Drugs: Sulfonylureas

---

5. Healthspan vs. Lifespan — Two Different Goals

Even though metformin hasn’t been proven to make people live longer, it might still improve healthspan—the number of years spent free of major diseases.

For example, in the DPPOS study, metformin users—especially men—had less coronary artery calcium (CAC), a sign of slower arterial aging (J Am Coll Cardiol, 2022).

However, it’s crucial to understand that not all arterial plaques contain calcium. Some plaques are non-calcified (soft plaques) and are rich in lipids and inflammatory cells.

These soft, non-calcium plaques are actually more dangerous because they are more prone to rupture, forming a blood clot that can suddenly block an artery and cause a heart attack or stroke.

So even if metformin users had less calcium buildup, that doesn’t necessarily mean they had fewer dangerous plaques—or lower heart risk overall. That’s why the DPPOS long-term results, showing no reduction in deaths or cardiovascular events, are so informative.

The ongoing Targeting Aging with Metformin (TAME) Trial aims to test whether metformin can delay multiple age-related diseases—but it isn’t designed to prove longer lifespan yet (American Federation for Aging Research, 2024).

---

6. What About Taking Metformin Without Diabetes?

At this point, there’s no medical justification for healthy people to take metformin just to live longer. The benefits are unproven, and the side effects—like gastrointestinal upset, vitamin B12 deficiency, and rarely lactic acidosis—are real.

Vitamin B₁₂ deficiency from long-term metformin use can lead to symptoms like fatigue, neuropathy (numbness or tingling in the hands and feet), memory problems, and even depression.

These effects can appear gradually and may be mistaken for aging or diabetic complications. For this reason, people taking metformin for extended periods should have their B₁₂ levels checked periodically and consider supplementation if levels are low.

Metformin remains an excellent drug for people with diabetes or prediabetes, but not a guaranteed “longevity pill.”

---

7. Proven Ways to Extend Life

While scientists continue to study “geroprotective” drugs, we already know what works:

• Exercise: Regular physical activity reduces all-cause mortality by up to 35 %.
• Weight control and good diet: Prevent diabetes and vascular disease.
• Adequate sleep and stress management
• No smoking, minimal alcohol

These interventions not only prolong life—they improve healthspan more effectively than any pill yet discovered.

---

8. Bottom Line

Metformin remains an important tool in diabetes prevention and treatment.
But the idea that it’s a proven “anti-aging drug” is not supported by strong evidence.

Conclusion

• The best long-term randomized trial (DPP/DPPOS) showed no reduction in heart disease or death with metformin.
• Observational “longevity” signals were likely statistical illusions caused by bias.
• Metformin may help delay disease (healthspan) but not yet proven to extend lifespan.
• Lifestyle remains the true longevity therapy.

---

Don’t Get Sick!

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.

Related:

1. The Hidden Truth: Diabetes Medications Manage, Not Truly Heal
2. Natural Supplements Don’t Prevent Diabetes Complications
3. Simple Daily Choices That Cut Heart Attack And Stroke Risks
4. Saturated Fat and Heart Disease: Understanding the Latest Science
5. Machine Learning Finds Your Hidden Heart Disease Risks
6. ApoB Reveals Hidden Heart Disease And Diabetes Risk Early
7. How to Interpret ApoB and ApoA1 Results
8. ApoB vs LDL Cholesterol: Which Predicts Heart Attacks Better
9. CAC And CTA Scans Help Detect Heart Disease Early
10. ApoB and ApoA1 Best Predict Heart Attack: How To Get Tested
11. ApoB vs LDL Cholesterol: Which Predicts Heart Attacks Better
12. Heart Attack Risk? Use The Framingham Risk Calculator And Lower It Now!
13. Discover Your Cardiac Age with This Free Calculator
14. Heart Rate Recovery Reveals Hidden Secrets About Your Heart
15. Drink Coffee At This Time To Slash Heart Attack Risk

References

1. Goldberg, Ronald B., et al. “Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program Outcomes Study.” Circulation, vol. 146, no. 21, 2022, pp. 1620–1632. https://doi.org/10.1161/CIRCULATIONAHA.121.056756. AHA Journals
2. Bannister, Craig A., et al. “Can People with Type 2 Diabetes Live Longer than Those without? A Comparison of Mortality in People Initiated with Metformin or Sulphonylurea Monotherapy and Matched, Non-Diabetic Controls.” Diabetes, Obesity and Metabolism, vol. 16, no. 11, 2014, pp. 1165–1173. https://pubmed.ncbi.nlm.nih.gov/25041462/. (Observational; vulnerable to bias.) PubMed
3. Wei, Min, et al. “Metformin and Pancreatic Cancer Survival: Real Effect or Immortal Time Bias?” Pancreatology, vol. 19, no. 5, 2019, pp. 681–687. https://pubmed.ncbi.nlm.nih.gov/30848544/. PubMed
4. Luo, Shan, et al. “Effects of Putative Metformin Targets on Phenotypic Age and Mortality: A Mendelian Randomisation Study.” The Lancet Healthy Longevity, vol. 4, no. 6, 2023, e335–e344. https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00085-5/fulltext. The Lancet
5. Konopka, Adam R., and David M. Nathan. “Taming Expectations of Metformin as a Treatment to Extend Human Lifespan.” Aging Cell, vol. 18, no. 1, 2019, e12831. https://pmc.ncbi.nlm.nih.gov/articles/PMC6544683/. PMC
6. Shadyab, Aline H., et al. “Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity among Older Women with Diabetes: A Target Trial Emulation.” The Journals of Gerontology: Series A, 2025, glaf095. https://doi.org/10.1093/gerona/glaf095. (Suggestive but not causal.) OUP Academic
7. American Federation for Aging Research (AFAR). “TAME—Targeting Aging with Metformin.” 2025. https://www.afar.org/tame-trial. (Trial aims/overview.) American Federation for Aging Research

© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment

As an Amazon Associate, I earn from qualifying purchases